The Centers for Medicare & Medicaid Services published final negotiated Medicare Part D prices for 15 drugs under the Inflation Reduction Act, including semaglutide-containing products (Wegovy, Ozempic), multiple oncology agents and respiratory therapies. CMS said the 2027 prices would have reduced net spending by about 44% had they been in effect in 2024, and estimated billions in Medicare savings and hundreds of millions in beneficiary out-of-pocket reduction. The list includes high-expenditure single-source branded medicines; negotiations concluded through offers, counteroffers and evidence review. Drugmakers either accepted final offers or reached agreements after revised counteroffers. The policy will have downstream effects on commercial pricing, manufacturer strategies, and legal challenges as some companies consider appeals.